Related Experiment Video
Updated: Oct 11, 2025
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Taraxasterol mitigates Con A-induced hepatitis in mice by suppressing interleukin-2 expression and its signaling in T
Xun-Jia Ye1, Rong Xu1, Si-Ying Liu1
1Department of Immunobiology, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Abstract:
Discovery of anti-inflammatory drugs that can suppress T lymphocyte activation and proliferation by inhibiting TCR/CD3 and IL-2/IL-2R signaling is still needed in clinic, though rapamycin and other related reagents have made great success. Taraxasterol (TAS) is an active ingredient of dandelion, an anti-inflammatory medicinal herb with low in vivo toxicity that has long been used in China. Yet the action mechanism of TAS on lymphocytes remains elusive. The anti-inflammatory effects of TAS were evaluated in C57BL/6 mouse primary lymphocytes stimulated with concanavalin A (Con A) in vitro and in mouse model of Con A-induced acute hepatitis in vivo. Our results showed that TAS significantly suppressed Con A-induced acute hepatitis in a mouse model, reducing the hepatic necrosis areas, the release of aminotransferases, and the production of IL-2 and other inflammatory cytokines. Supporting this, in vitro study also showed that TAS reduced the production of IL-2 and the expression of IL-2 receptor subunit α (CD25) upon the stimulation of Con A, which was likely mediated by suppressing NF-κB activation. The downstream pathways of IL-2/IL-2R signaling, including the activation of PI3K/PDK1/mTOR, STAT3 and STAT5, were also suppressed by TAS. Consistently, Con A-induced T cell proliferation was also inhibited by TAS in vitro. Our data indicate that TAS can suppress both T lymphocyte activation and cell proliferation by down-regulating IL-2 expression and its signaling pathway thereby ameliorating Con A-induced acute hepatitis, highlighting TAS as a potential drug candidate for treating inflammatory diseases including autoimmune hepatitis.
Insights
Taraxasterol (TAS), derived from dandelion, effectively suppresses T lymphocyte activation and proliferation. This natural compound ameliorates acute hepatitis by inhibiting key inflammatory signaling pathways, showing promise for autoimmune disease treatment.
Area of Science:
- Immunology
- Pharmacology
- Natural Products Chemistry
Background:
- Novel anti-inflammatory drugs targeting T lymphocyte activation and IL-2/IL-2R signaling are clinically needed.
- Taraxasterol (TAS), a dandelion component, possesses anti-inflammatory properties but its mechanism on lymphocytes is unclear.
Purpose of the Study:
- To investigate the anti-inflammatory mechanism of Taraxasterol (TAS) on T lymphocytes and its efficacy in a mouse model of acute hepatitis.
Main Methods:
- In vitro studies using mouse primary lymphocytes stimulated with concanavalin A (Con A).
- In vivo evaluation in a Con A-induced acute hepatitis mouse model.
- Analysis of cytokine production, receptor expression, and downstream signaling pathways (NF-κB, PI3K/PDK1/mTOR, STAT3, STAT5).
Main Results:
- TAS significantly reduced Con A-induced acute hepatitis, decreasing liver damage and inflammatory markers.
- In vitro, TAS inhibited IL-2 production and CD25 expression, likely via NF-κB suppression.
- TAS suppressed IL-2/IL-2R downstream signaling and Con A-induced T cell proliferation.
Conclusions:
- TAS suppresses T lymphocyte activation and proliferation by down-regulating IL-2 expression and signaling.
- TAS ameliorates Con A-induced acute hepatitis, indicating its potential as a therapeutic agent for inflammatory and autoimmune diseases.
